Pharmaceuticals This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 8.

FDA to decide fate of GSK, Theravance COPD drug by Dec. 18
GlaxoSmithKline and Theravance Inc. will get a Food and Drug Administration decision by Dec. 18 on their experimental treatment for chronic obstructive pulmonary disease. GSK and South San Francisco's Theravance (NASDAQ: THRX) said their FDA application for Anoro, previously known as UMEC/VI, was accepted by the agency. That sets the FDA's 10-month approval clock in motion. Anoro, a once-a-day drug, is a combination of two bronchodilator molecules: GSK-573719, or UMEC or umeclidinium bromide, and…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 19, 2013 Category: Pharmaceuticals Authors: Ron Leuty Source Type: research

Vitamin C in High Doses Related to Kidney Stone Formation in Men
If you are a person who believes in “moderation”, and that “less is sometimes better", you may want to take note of some recent research published in JAMA Internal Medicine regarding the role of high dose vitamin C and kidney stone formation in men.
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Robert Glatter, MD Source Type: news

UAB adds clinical trials unit
The University of Alabama at Birmingham just opened a $1.6 million facility that will ease the process of taking part in clinical trials. The university announced today that its Phase 1 Clinical Trials Unit, a part of the UAB Center for Clinical and Translational Science, has opened. The Clinical Trials Unit, a nearly 8,000-square-foot expansion of the CCTS Clinical Research Unit that began operations in 2008, is on the 15th floor of the Jefferson Tower building at 625 19th St. South. Patients…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 19, 2013 Category: Pharmaceuticals Authors: Yann Ranaivo Source Type: research

How Vaccines Have Changed Our World In One Graphic
The data in this graphic come from the web site of the Centers for Disease Control & Prevention, but a graphic designer in Purchase, N.Y., named Leon Farrant has created a graphic that drives home what the data mean. Below is a look at the past morbidity (how many people became
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

FTC Gets Muscle in Policing Mergers
The U.S. Supreme Court gave more muscle to the Federal Trade Commission's ability to police hospital mergers, putting limits on the circumstances that exempt local governments from antitrust law.
Source: WSJ.com: Health - February 19, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Novartis pay criticism unlikely to abate
With its AGM due on Friday, the group is still likely to face an uncomfortable grilling over aspects of its corporate governance arrangements
Source: FT.com - Drugs and Healthcare - February 19, 2013 Category: Pharmaceuticals Source Type: news

Are We Hard-Wired to Hate Exercise?
Discipline and motivation aside, researchers are looking at the physiological reasons behind why some people enjoy exerting themselves and others don't.
Source: WSJ.com: Health - February 19, 2013 Category: Pharmaceuticals Tags: FREE Source Type: news

5 Worst Age Give-Aways - And 5 Best Fixes Celeb-Style
When I was a teenager, my Paris-educated grandmother once remarked to me that the reason she favored her signature silk scarves was because "the neck will always give you away."
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Melanie Haiken Source Type: news

The Novartis Board Insulted Shareholders With Hush Money For Dan Vasella
The battle over executive compensation took an unusual turn this week when Novartis responded to an outpouring of anger over a non-compete deal that would have given outgoing chairman Dan Vasella as much as $78 million over six years (see this). The board had originally justified its decision in order to "protect" the drugmaker, since Vasella knows "the company’s business intimately, having built the leading R&D organization and personally recruited most of the top executives." In other words, the payoff was hush money designed to keep him from telling secrets to competitors.
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Ed Silverman Source Type: news

FTC Can Challenge Hospital Mergers
The U.S. Supreme Court gave more muscle to the Federal Trade Commission's ability to police hospital mergers, putting limits on the circumstances that exempt local governments from antitrust law.
Source: WSJ.com: Health - February 19, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Medtronic's Profit Rises on Higher Revenue
Medtronic's quarterly earnings rose 5.7% as the medical-devices company reported stronger revenue despite soft markets for some spine and heart products.
Source: WSJ.com: Health - February 19, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Developing world boost for GM crops
Genetically modified crops continue to march across farmlands with their planted area increasing by 6 per cent last year to 170m hectares
Source: FT.com - Drugs and Healthcare - February 19, 2013 Category: Pharmaceuticals Source Type: news

SPO Partners with HoMedics LLC
Focus on new consumer wellness products for OTC sales NEW YORK, February 19, 2013 -- (Healthcare Sales & Marketing Network) --SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devic... Devices, Monitoring, DistributionSPO Medical, HoMedics LLC, pulse oximeter, Optimetrix
Source: HSMN NewsFeed - February 19, 2013 Category: Pharmaceuticals Source Type: news

MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO
MONTREAL, CANADA--(Healthcare Sales & Marketing Network) - MethylGene Inc. ("MethylGene" or the "Company") (MYG.TO) today announced that Mark J. Gergen has been appointed to the position of Executive Vice President and Chief Operations ... Biopharmaceuticals, PersonnelMethylGene
Source: HSMN NewsFeed - February 19, 2013 Category: Pharmaceuticals Source Type: news

FTC Can Challenge Local Hospital Mergers
The U.S. Supreme Court gave more muscle to the Federal Trade Commission's ability to police hospital mergers, putting limits on the circumstances that exempt local governments from antitrust law.
Source: WSJ.com: Health - February 19, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Dinosaur Doctors And The Death Of Paternalistic Medicine
Healthcare delivery has morphed through the decades, and we are in the infancy of a new and exciting phase – the age of patient empowerment. What exactly is this? Let me first share a story of what it is not in the realm of physician-patient interaction.
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Carolyn McClanahan Source Type: news

FiercePharma's Most Influential People: A Short History of Leadership
FiercePharma has released its second annual list of most influential people in biopharma, and it is tempting to look at the names and seek a pattern that can explain who did, or did not receive the honor. Let me start by stressing that searching for trends in 50 data points spanning only 2 years is statistically daring, and your guess is as good as mine. I hope nonetheless that this attempt can prompt insightful discussions on what is effective leadership in an industry poised for profound transformation.
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Bernard Munos Source Type: news

Here Comes The Boom: CMS Slashes Medicare Advantage; 'Disarray For Many Seniors'
Though Democrats denied it during the 2012 campaign, Obamacare cut Medicare by $716 billion in order to partially fund $1.9 trillion in new entitlement spending over the next ten years. A big chunk of those Medicare cuts came from the market-oriented Medicare Advantage program. Cleverly, the Obama administration postponed the Medicare Advantage cuts until after the election, so as to persuade seniors that everything would be just fine. But the election is over. On Friday, the administration announced that it would be significantly reducing funding for the popular program. Obama's proposal, according to one analyst, “woul...
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Avik Roy Source Type: news

Amicus Therapeutics Slumps on New Fabry Drug Data
Associated Press - Feb. 15, 2013 NEW YORK -- Shares of Amicus Therapeutics Inc. tumbled Friday after the company reported new negative results from a clinical trial of an experimental treatment for...
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin for acromegaly and neuroendocrine tumors
Basel, 18 February 2013-Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma’s proprietary...
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Looking for a Way to Reduce Medicare Spending? Look No Further than Part D
As it becomes clear the President Obama is making Medicare a key topic for discussion within the broader context of federal spending, Democrats and Republicans have an opportunity to pursue common-sense reforms that preserve the program while achieving bipartisan support for fixing what isn't working. Despite ongoing reservations, I believe that some parts of the Affordable Care Act can conceivably be implemented with minimal dislocation, but only if the right policies are embraced by the administration. And that’s why I think that the president is making a mistake in proposing potentially damaging changes to arguably th...
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Doug Schoen Source Type: news

Xeris Pharma collects $1.7M funding
Xeris Pharmaceuticals Inc. received $1.7 million of planned $3 million financing. The Austin-based company collected the capital from 28 investors, according to a Feb. 14 filing with the U.S. Securities and Exchange Commission. Xeris Pharmaceuticals, which was founded in 2005, develops injectable drugs to treat endocrine and metabolic diseases. The company employed five workers in 2011. Sign up for free email updates: Morning Call ABJ-E Earlier this month, it was awarded a $1.9 million…
Source: bizjournals.com Health Care:Physician Practices headlines - February 19, 2013 Category: American Health Authors: Christopher Calnan Source Type: research

The Best- And Worst-Paying Jobs For Doctors
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Carolyn McClanahan Source Type: news

Will Sequester End Drug Approvals? Not Unless White House Wants it to
As sequester looms likely, there’s focus on what it means for Federal agencies, including the Food and Drug Administration (FDA). Last time FDA had its budget clipped (by a much smaller amount) it used the shortfall as reason to back off some of its commitments under the Prescription Drug User Fee Act (PDUFA) to review applications on pre-determined timetables. What will happen this time?
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Scott Gottlieb Source Type: news

Novartis Axes Chairman's Exit Pay
Swiss drug maker Novartis abandoned its plan to pay departing Chairman Daniel Vasella $78 million following pressure from shareholders.
Source: WSJ.com: Health - February 19, 2013 Category: Pharmaceuticals Tags: FREEEUROPE Source Type: news

Hyperconnectivity: The Future is Now
I’ve spent my life dreaming of a hyperconnected world. And I’ve dedicated my life to creating new modes of communication that make this world possible. The hyperconnected world is a world where things that need to communicate will and do communicate. Truly, your dishwasher can talk to the power grid, your fuel sensor can talk to the gas station, your grass can talk to your sprinklers. This has been my vision for the future for years. Well, the future is now.
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Vivek Ranadivé Source Type: news

Vioxx and Diclofenac: Why Are Two Heart Risky Pain Drugs Viewed Differently?
More than a decade ago, Merck launched Vioxx (rofecoxib), one of the first of a new class of pain relievers known as COX-2 inhibitors. These compounds, by virtue of their mode of action, were deemed to be as potent arthritis pain relievers as traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, but were believed to be safer than NSAIDs since they caused less gastrointestinal distress. Vioxx was an immediate success with physicians and patients. New prescriptions for Vioxx soared.
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: John LaMattina Source Type: news

Ex-Pfizer Exec Muses on Industry's Image
[the Day, New London, Conn.] From Day, The (New London, CT) (February 17, 2013) Feb. 17--For a man like John LaMattina who lived and breathed science, stepping into the daytime television environment of...
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Chiasma Teams With Roche
[Globes, Tel Aviv, Israel] From Globes (Tel Aviv) (February 18, 2013) Feb. 18--Chiasma Inc., which develops oral versions of biological drugs, has signed a strategic development agreement with Roche AG (SWX: ROG). The deal...
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Quintiles Looks to Go Public
[the Herald-Sun, Durham, N.C.] From Herald-Sun (Durham, NC) (February 18, 2013) Feb. 18--DURHAM -- Quintiles, the Durham-based multinational company that manages clinical trials and provides other contract services for...
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Report: Exec Paid $78M to Keep Secrets
From UPI Business News (February 18, 2013) A pay package of $78 million for the departing chairman of drug company Novartis has caused an uproar in Switzerland, observers say. The New York Times reported Monday that Novartis plans to pay Chairman...
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

12 Ways to Be the Leader Everyone Wants to Work For
It’s not easy being a manager these days. You’re responsible for recruiting, hiring, training, coaching, modeling, engaging, monitoring, motivating, anticipating, prioritizing, planning, evaluating, clarifying, adapting, envisioning, directing, disciplining, reinforcing, reporting, recognizing, budgeting, and building alliances. And that’s all before lunch. And if you struggle with just one, your reports will say you’re over your head.
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Jeff Schmitt Source Type: news

Dune Medical Devices Announces European Union Approval of the MarginProbe(R) System Type 1.2
CE Approval Allows Marketing of Portable, Compact MarginProbe System BOSTON, Feb. 19, 2013 -- (Healthcare Sales & Marketing Network) -- Dune Medical Devices announced today that it has received CE approval for compliance with the European Union's medic... Devices, Oncology, RegulatoryDune Medical Devices, MarginProbe, breast cancer
Source: HSMN NewsFeed - February 19, 2013 Category: Pharmaceuticals Source Type: news

The 7 Habits of Highly Patient Centric Providers
Since Dr. Farzad Mostashari's (the U.S. "healthIT czar") keynote presentation at the 2012 HIMSS conference, I've repeatedly heard that 2013 is the year of patient engagement. Dr. Mostashari unveiled the latest requirements to tap stimulus dollars and virtually all of the new items were around patient engagement. As Lygeia Ricciardi of the ONC recently stated, the ONC is going all-in on patient engagement. Why the focus
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Dave Chase Source Type: news

Independent Study Demonstrates Clinical Advantages Of Kiva(R) Over Balloon Kyphoplasty
Spine Publishes Results Showing Kiva Restored Deformity and Reduced Extravasation SANTA CLARA, Calif., Feb. 19, 2013 -- (Healthcare Sales & Marketing Network) -- An independent, prospective, randomized study of patients with vertebral compression fract... Devices, Neurosurgery, OrthopaedicBenvenue Medical, vertebral compression fracture, balloon kyphoplasty, Kiva VCF
Source: HSMN NewsFeed - February 19, 2013 Category: Pharmaceuticals Source Type: news

Regeneron and Bayer Initiate Phase 3 Trial of Eylea (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
TARRYTOWN, N.Y. and BERLIN, Feb. 19, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated a new Phase 3 trial (named VIVID EAST-DME) to evaluate the efficacy and safety of...
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
CARLSBAD, Calif., Feb. 19, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7.5 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 2/3 clinical study...
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Novartis Board of Directors and Dr. Daniel Vasella agree to cancel the non-compete agreement and all related compensation; Decision taken to address concerns of stakeholders
Basel, 19 February 2013 - Novartis announced that the Novartis Board of Directors and Dr. Daniel Vasella have agreed to cancel his non-compete agreement with Novartis and all related conditional compensation. The agreement was to take effect after...
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Sanofi India to double consumer healthcare biz to Rs 1,000 cr
Sanofi India (previously known as Aventis Pharma) today said it aims to double its consumer healthcare business in the next five years.
Source: The Economic Times Healthcare and Biotech News - February 19, 2013 Category: Pharmaceuticals Source Type: news

GSK and Theravance announce FDA acceptance of New Drug Application (NDA) submission in the US for ANORO ELLIPTATM for COPD
Source: GSK news - February 19, 2013 Category: Pharmaceuticals Source Type: news

Omega Healthcare plans to strengthen operations offshore
Healthcare service provider Omega Healthcare has planned to strengthen operations in the offshore healthcare market with the inauguration of its fourth facility in the country and third in Tamil Nadu today.
Source: The Economic Times Healthcare and Biotech News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Why Spend $900 Billion On Health Insurance?
Although Obamacare is intensely focused on getting insurance access to all, one must ask: Is healthcare insurance part of the problem or part of the solution?
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Michael Bell Source Type: news

Six Healthy Carbs To Help You Lose Weight
English: Dagwinkel foodstores fresh fruits & vegetables (Photo credit: Wikipedia)
Source: Forbes.com Healthcare News - February 19, 2013 Category: Pharmaceuticals Authors: Robert Glatter, MD Source Type: news

Novartis scraps chairman’s $78m payout
Mounting anger from shareholders forces the Swiss pharmaceutical group into a U-turn over a controversial ‘golden gag’ for Daniel Vasella
Source: FT.com - Drugs and Healthcare - February 19, 2013 Category: Pharmaceuticals Source Type: news

Extractables and Leachables for Medical Devices: Meeting the 510(k) Requirements
Recent changes in the FDA's 510(k) requirements for medical device applications have spawned many inquiries from clients on how to address the request for extractables, leachables and drug compatibility data.
Source: Pharmaceutical Technology - February 19, 2013 Category: Pharmaceuticals Source Type: news

Analytical Challenges Presented by Leachables from Sample Container Closure Systems in Drug Products
Leachables are compounds that migrate into a drug product from the sample container closure system (SCC) under nromal storage conditions.
Source: Pharmaceutical Technology - February 19, 2013 Category: Pharmaceuticals Source Type: news

FDA is Increasing Regulations on Excipients Worldwide – What Can Your Company Do to Reduce Risk?
Since 2008, when patient deaths were first linked to tainted raw materials used in the manufacture of heparin, the US Food and Drug Administration (FDA) and other regulatory agencies have been taking a much closer look at drug manufacturing supply ch…
Source: Pharmaceutical Technology - February 19, 2013 Category: Pharmaceuticals Source Type: news

What Will Eventually Wake Up the US Pharma Industry to the Importance of Quality; the Stick, or the Carrot?
Roll the clock back to the early 2000s - groundbreaking discussions between FDA and Industry that led to the 'cGMP for the 21st Century' philosophy - science and risk-based approaches to quality.
Source: Pharmaceutical Technology - February 19, 2013 Category: Pharmaceuticals Source Type: news

Proposed New European Regulation for Medical Devices to Replace 93/42/EEC and 90/385/EEC
The Commission proposal for a new regulation to cover medical devices and active implantable medical devices was published on 26 September 2012.
Source: Pharmaceutical Technology - February 19, 2013 Category: Pharmaceuticals Source Type: news

New Zealand to Propose Plain Cigarette Packs
Following Australia's lead, New Zealand's government said it will introduce "plain-packaging" legislation for tobacco products by the end of the year.
Source: WSJ.com: Health - February 19, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news